2012-11-08 07:49:56 - VP at BMS to Speak at Cytokines and Inflammation Conference Jan 31 – Feb 1, 2013, San Diego-CA
Juan Carlos Lopez-Talavera, Vice President of Global Research and Development and Medical Affairs at Bristol Myers Squibb will give a featured presentation on “Development of Peginterferon Lambda for the Treatment of Chronic Hepatitis C and Hepatitis B” at the 11th Cytokines and Inflammation Conference to be held in San Diego, CA on January 31 – February 1, 2013 by GTC.
Peginterferon lambda-1a (Lambda), the pegylated form of interferon lambda, a type-III interferon, is currently being investigated as a therapeutic alternative to the current standard of care. Lambda binds to a unique receptor with a more restricted distribution than the receptor for type 1-alfa interferons. Dr. Lopez-Talavera will address the current challenges in treating HCV and HBV, describe the development of
peginterferon-lambda therapy, and highlight the results from phase 2 clinical trials and planned phase 3 programs.
Benefits of this presentation include:
- What are the key unmet needs and challenges with the current standard of care for patients with chronic HCV and HBV? Limited efficacy and Side effects and tolerability problems
- What is the profile of peginterferon lambda (Lambda)? Describe Lambda mechanism of action, highlight differences between Lambda and alfa-interferons
- What are the current clinical trials with Lambda for HCV and HBV?
Dr. Lopez-Talavera joined Bristol‐Myers Squibb in 2005 and serves currently as Vice President of Research and Development, Global Development and Medical Affairs. He is responsible for developing and implementing the global strategy for interferon lambda and its combinations with direct acting antivirals in HCV and HBV. Previously, he was Senior Medical Director with Roche Laboratories. He was Assistant Professor with the Divisions of Gastroenterology and Hepatology, and Endocrinology and Pathology at the University of Pittsburgh Medical Center. Previously, Dr. Lopez-Talavera was Associate Professor of Medicine at the Universidad Autónoma de Barcelona and Attending Physician of the Liver Unit at the Hospital General Universitari Vall D’Hebron in Barcelona.
The GTC Cytokines and Inflammation conferences have become an established meeting point for academic scientists and industry clinical developers to exchange their complementary approaches in the field of cytokine biology. The organizations participating are a great selection of innovative medical organizations from academia (City of Hope, NCI, NIH, USC, Sanford-Burnham, Cleveland Clinic, UCLA, University of Florida, etc.), industry (Amgen, Bristol-Myers Squibb, Genentech, HUMIGEN, MedImmune, Biogen Idec, Merck Serono, Novo Nordisk, etc.) and the US FDA.
This conference is also part of the 2nd Novel Immunotherapeutics Summit, which consists of this track and three other concurrent tracks:
1) 5th Immunotherapeutics & Immunomonitoring
2) 2nd Allergy & Respiratory Drug Discovery
3) Immunotoxicity & Immunogenicity
For more information, please visit www.gtcbio.com